Insulin, Total
Label Mnemonic: | INSLT |
Epic code: | LAB7389 |
Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Chemistry
6240 RCP
356-3527
6240 RCP
356-3527
Specimen(s):
Plasma
Collection Medium:
![]() |
Plasma Separator Tube 4.5 mL |
Alternate
Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood from light green top tubes or TWO
Microtainer® devices from a fasting patient.
Delivery Instructions:

Turn Around
Time:
1 hour (upon receipt in laboratory)
Reference Range:
2.6 - 24.9 μU/mL (fasting)
Comments:
This assay may be significantly impacted by high-dose biotin (>5 mg
dose) taken within previous 12 hours. High concentrations of biotin
may lead to falsely decreased results. These concentrations may be
found in patients taking over-the-counter supplements with biotin
content much higher than nutritional requirements for biotin.
Specimens should not be collected until at least 12 hours after the
last dose.
Fasting for at least 8 hours prior to collection is recommended.
This assay has 100% cross-reactivity with endogenous insulin and recombinant human insulin (e.g., Novolin R and Novolin N). It does not recognize the insulin analogs lispro (Humalog), aspart (NovoLog), and glargine (Lantus). The mail-out test "Insulin, Random, Serum or Plasma" does cross-react with the insulin analogs and may be useful in determining whether a patient is taking one of these analogs (e.g., evaluating whether surreptitious insulin use may be causing otherwise unexplained hypoglycemia).
Fasting for at least 8 hours prior to collection is recommended.
This assay has 100% cross-reactivity with endogenous insulin and recombinant human insulin (e.g., Novolin R and Novolin N). It does not recognize the insulin analogs lispro (Humalog), aspart (NovoLog), and glargine (Lantus). The mail-out test "Insulin, Random, Serum or Plasma" does cross-react with the insulin analogs and may be useful in determining whether a patient is taking one of these analogs (e.g., evaluating whether surreptitious insulin use may be causing otherwise unexplained hypoglycemia).
Test
Limitations:
The assay is unaffected by icterus (bilirubin is less than 90 mg/dL), lipemia (Intralipid is less than 1800 mg/dL) and biotin is less than 60 ng/mL (criterion: recovery within plus or minus 10% of initial value). Hemolysis is less than 60 mg/dL. Samples from patients treated with bovine or porcine insulin sometimes contain anti-insulin antibodies which can affect the test results.(1-2) As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or have received them for diagnostic purposes. Elecsys Insulin contains additives which minimize these effects. In rare cases, interference due to extremely high titers of antibodies to streptavidin can occur. For diagnostic purposes, Insulin findings should always be assessed in conjunction with the patient's medical history, clinical examination and other findings. (1) Fiedler, H. Basiswissen Labordiagnostik: Diabetes mellitus und metabolisches Syndrom. Roche Diagnostics Brochure 1999;14,67 Cat No. 1951769. (2) Tietz NW. Clinical Guide To Laboratory Tests. 3rd ed. Philadelphia, Pa: WB Saunders Co, 1995:366-367.
Methodology:
Electrochemiluminescence Immunoassay
CPT Code:
83525
See also:
Insulin, Random (Mailout), Serum or Plasma
Insulin, Random (Mailout), Serum or Plasma
See Additional Information:
Specimens Requiring Immediate Delivery
Fasting Specimen Requirements
Biotin Interference with Immunoassays
Specimens Requiring Immediate Delivery
Fasting Specimen Requirements
Biotin Interference with Immunoassays